However, TfRMAb-EPO dosing resulted in a 30–40% reduction in Aβ load, which, though significant and in line with the reduction seen with murine analog of Lecanemab in AD mouse models [32, 33], is modest compared to the remarkable > 70% reduction seen in the current study. This evidence concerns the gene EPO and Alzheimer disease.